Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variants.
about
The C Terminus of HIV-1 Tat Modulates the Extent of CD178-mediated Apoptosis of T CellsHIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.HIV-1 clade B Tat, but not clade C Tat, increases X4 HIV-1 entry into resting but not activated CD4+ T cells.Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine.Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus.Molecular characterization of full-length Tat in HIV-1 subtypes B and CHuman immunodeficiency virus type 1 subtype C Tat fails to induce intracellular calcium flux and induces reduced tumor necrosis factor production from monocytesA monoclonal antibody directed against a conformational epitope of the HIV-1 trans-activator (Tat) protein neutralizes cross-cladeAssociation between different anti-Tat antibody isotypes and HIV disease progression: data from an African cohortImpact of Tat Genetic Variation on HIV-1 DiseaseA mutant Tat protein inhibits infection of human cells by strains from diverse HIV-1 subtypesIntradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial.Homonuclear 1H NMR and circular dichroism study of the HIV-1 Tat Eli variantGeneration and characterization of neutralizing human monoclonal antibodies against human immunodeficiency virus type 1 Tat antigenWhat does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine?HIV-1 Tat Binding to PCAF Bromodomain: Structural Determinants from Computational Methods.Sequence variation within the dominant amino terminus epitope affects antibody binding and neutralization of human immunodeficiency virus type 1 Tat protein.Identification of a highly conserved surface on Tat variants.
P2860
Q22248066-083AA80B-723E-4D39-8DEC-7F1ACB734DADQ30381447-CAEE85A2-A1D8-4111-BD68-77D8B122E42EQ33581852-783519C7-90EC-42EE-BCFD-5E82656073B6Q34488930-423CB935-BB76-4470-A629-3FB431BB4E11Q35129224-BC8A4531-F71E-4E6F-98FF-9CA8F9F8C923Q35483696-5CEB46B4-A6EB-4102-A8E9-494302F4F552Q35857699-913D8AEC-AD7B-415F-A100-27F6C7D3A30EQ35874415-0F4EF0F0-0743-491F-8FA6-AC1F083A15BBQ36083803-1E98E0C2-A8B1-48B5-A20C-ECF46D3BF199Q36148507-CE1EA142-8EAF-44E9-A6DA-4AEAF7066C38Q36306794-D3842FCF-0908-4E34-8B15-7FC37670DB66Q36758540-50E3B430-86E2-4919-92EC-5C43C1BC9ED5Q36917002-83D15535-480D-4E24-B7F3-1F89FC5EC72BQ37010956-E8652978-3F5F-4C90-B307-5FE78BE7DDC2Q37220038-D19D3173-20AA-4A19-8CF1-EB152CE567CDQ39215152-D3D10F1B-B679-45CA-9CA1-BD70E3DE5D89Q40273841-3066987C-30F4-49C8-B766-CAB110364B40Q41468434-8198252B-A9FC-497D-8048-20A4D578B036
P2860
Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variants.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Tat HIV-1 primary and tertiary ...... ainst non-homologous variants.
@en
Tat HIV-1 primary and tertiary ...... ainst non-homologous variants.
@nl
type
label
Tat HIV-1 primary and tertiary ...... ainst non-homologous variants.
@en
Tat HIV-1 primary and tertiary ...... ainst non-homologous variants.
@nl
prefLabel
Tat HIV-1 primary and tertiary ...... ainst non-homologous variants.
@en
Tat HIV-1 primary and tertiary ...... ainst non-homologous variants.
@nl
P2093
P2860
P356
P1476
Tat HIV-1 primary and tertiary ...... ainst non-homologous variants.
@en
P2093
Anne Walburger
Catherine Grégoire
David L Yirrell
Didier Esquieu
Erwann P Loret
Jean de Mareuil
Jean-Marie Péloponèse
Murielle Solomiac
Sandrine Opi
P2860
P304
35915-35919
P356
10.1074/JBC.M204393200
P407
P577
2002-06-21T00:00:00Z